Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08) Conference

Wen, PY, Yung, WKA, Lamborn, K et al. (2006). Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08) . NEURO-ONCOLOGY, 8(4), 454-454.

cited authors

  • Wen, PY; Yung, WKA; Lamborn, K; Cloughesy, T; DeAngelis, LM; Fine, HA; Chang, SM; Robins, HI; Fink, K; Abrey, LE; Lassman, AB; Mehta, M; Kesari, S; Kim, L; Stiles, C; Egorin, M; Kaplan, R; Murgo, A; Prados, MD

sustainable development goals

authors

date/time interval

  • September 14, 2006 -

publication date

  • October 1, 2006

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • Vienna, AUSTRIA

Conference

  • 7th Congress of the European-Association-for-Neuro-Oncology (EANO)

publisher

  • DUKE UNIV PRESS

start page

  • 454

end page

  • 454

volume

  • 8

issue

  • 4